Skip to main content

Table 3 Median overall survival time in the studies

From: The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

Study Median survival time(months) Median ratio pvalue
  TS +/high TS -/low   
Bepler et al. [6] 27.8 27 0.97 0.272
Chang et al. [30] 6.7 9.5 1.42 0.688
Chen et al. [21] 10 21.4 2.14 0.09
Sun et al. [17] 18.9 22.3 1.18 0.106
Igawa et al. [31] 8.6 14.7 1.71 0.04
Pool 14.4 19.0 1.32(95% CI 0.92-2.72) 0.24
  1. Patients with +/high expression of TS who received pemetrexed-based chemotherapy had a median overall survival time of 14.4 months; patients with -/low expressionof TS had a median overall survival of 19.0 weeks. Although patients with -/low expression of TS perform a longer median overall survival time than those with +/high expression of TS, the difference was not statistically significant (p = 0.24).